Tumores Mamários

Nova pesquisa mostra que o excesso de diagnósticos (overdiagnosis) de câncer de mama não é tão comum como se pensava.

8 Mar, 2022 | 17:42h

Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

How often is breast cancer overdiagnosed? New research finds true cases far outweigh false alarms – STAT

Breast cancer overdiagnosis may not happen as frequently as previously thought – ACP Internist

---

Riscos de outros tipos de câncer, além dos cânceres de mama e de ovário, associados às variantes patogênicas BRCA1 e BRCA2.

3 Mar, 2022 | 15:45h

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology

Comentário: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge

---

Estudo randomizado | Indicação de exercício precoce e com supervisão após cirurgia de câncer de mama melhora a função do ombro e a qualidade de vida relacionada a saúde.

1 Mar, 2022 | 15:30h

Resumo: Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT – Health Technology Assessment

Relatório completo: Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT – Health Technology Assessment

Conteúdo relacionado: RCT: Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema.

---

Revisão narrativa do painel de especialistas AJR | Algoritmos de rastreamento em mamas densas.

24 Fev, 2022 | 15:35h

Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review – American Journal of Roentgenology

---

M-A | Imunoterápicos combinados com quimioterapia em comparação à quimioterapia isolada para câncer de mama triplo-negativo.

17 Fev, 2022 | 14:50h

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis – Frontiers in Oncology

---

M-A | Inibidores de aromatase vs. tamoxifeno em mulheres na pré-menopausa com câncer de mama inicial positivo para receptor de estrogênio tratadas com supressão ovariana.

14 Fev, 2022 | 15:34h

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials – The Lancet Oncology

Comentários:

Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay

Aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in premenopausal as well as postmenopausal women – Cancer Research UK

---

Estudo randomizado | Sobrevida livre de evento com pembrolizumabe no câncer de mama inicial triplo-negativo.

11 Fev, 2022 | 14:15h

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário (antes da publicação): KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer – The ASCO Post

---

Atualização da diretriz de recomendação ASCO sobre quimioterapia adjuvante ótima e terapia-alvo | Abemaciclibe com terapia endócrina no tratamento do câncer de mama de alto risco.

10 Fev, 2022 | 13:28h

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update – Journal of Clinical Oncology

---

Estudo randomizado| Uso profilático de luvas compressoras reduz a incidência de edema de braço em mulheres sob alto risco de linfedema relacionado a câncer de mama.

4 Fev, 2022 | 17:14h

Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema: A Randomized Controlled Trial – Journal of Clinical Oncology

---

Impacto do câncer residual após quimioterapia neoadjuvante e desfechos de sobrevida de longo prazo no câncer de mama: análise multicêntrica de 5.161 pacientes.

4 Fev, 2022 | 15:42h

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients – The Lancet Oncology

Comentário: Long-Term Outcomes According to Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer – The ASCO Post

---